The stock of Eli Lilly and Co (NYSE:LLY) is a huge mover today! About 1.58M shares traded hands. Eli Lilly and Co (NYSE:LLY) has risen 11.25% since March 9, 2016 and is uptrending. It has outperformed by 3.83% the S&P500.
The move comes after 9 months positive chart setup for the $87.83B company. It was reported on Oct, 12 by Barchart.com. We have $113.90 PT which if reached, will make NYSE:LLY worth $36.01B more.
Analysts await Eli Lilly and Co (NYSE:LLY) to report earnings on October, 25 before the open. They expect $0.94 EPS, up 5.62% or $0.05 from last year’s $0.89 per share. LLY’s profit will be $1.02 billion for 21.48 P/E if the $0.94 EPS becomes a reality. After $0.86 actual EPS reported by Eli Lilly and Co for the previous quarter, Wall Street now forecasts 9.30% EPS growth.
Eli Lilly and Co (NYSE:LLY) Ratings Coverage
Out of 15 analysts covering Eli Lilly and Company (NYSE:LLY), 14 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 93% are positive. Eli Lilly and Company has been the topic of 40 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The firm has “Outperform” rating by Cowen & Co given on Monday, August 24. The rating was initiated by Berenberg with “Buy” on Thursday, August 27. BMO Capital Markets upgraded the shares of LLY in a report on Monday, November 16 to “Outperform” rating. The firm has “Outperform” rating given on Tuesday, October 13 by Leerink Swann. On Monday, December 28 the stock rating was maintained by Leerink Swann with “Outperform”. The rating was maintained by Leerink Swann with “Outperform” on Thursday, November 12. The stock has “Outperform” rating given by Leerink Swann on Monday, May 2. The firm has “Buy” rating given on Tuesday, September 27 by Goldman Sachs. Atlantic Securities initiated Eli Lilly and Co (NYSE:LLY) on Friday, December 18 with “Overweight” rating. The rating was initiated by Societe Generale with “Hold” on Wednesday, April 6.
According to Zacks Investment Research, “Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products. The company directs its research efforts primarily toward the search for products to diagnose, prevent and treat human diseases. The company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production.”
Insitutional Activity: The institutional sentiment increased to 1.07 in Q2 2016. Its up 0.36, from 0.71 in 2016Q1. The ratio is positive, as 54 funds sold all Eli Lilly and Co shares owned while 365 reduced positions. 88 funds bought stakes while 362 increased positions. They now own 814.98 million shares or 2.31% less from 834.25 million shares in 2016Q1.
Vantage Lc reported 185,261 shares or 1.52% of all its holdings. Point72 Asset Management Lp holds 0.72% or 1.35M shares in its portfolio. Manufacturers Life Insurance The has 0.23% invested in the company for 1.88M shares. Moreover, Jp Marvel Invest Advisors Ltd Liability Co has 1.62% invested in Eli Lilly and Co (NYSE:LLY) for 58,844 shares. Qcm Cayman accumulated 0.09% or 2,637 shares. Blackrock Investment Management Ltd Company, a New Jersey-based fund reported 2.38M shares. Johnson Fincl Group Inc Inc last reported 33,796 shares in the company. The Massachusetts-based Ipswich Invest Mngmt Commerce Incorporated has invested 0.32% in Eli Lilly and Co (NYSE:LLY). Doheny Asset Management Ca last reported 0.11% of its portfolio in the stock. Cap Guardian Tru Co, a California-based fund reported 1.56 million shares. Nelson Van Denburg Campbell Wealth Mgmt Grp Inc Limited Liability Company last reported 0.08% of its portfolio in the stock. M&R Cap Mngmt accumulated 2,691 shares or 0.06% of the stock. Parametrica Ltd holds 2,751 shares or 0.32% of its portfolio. Gabelli Funds Ltd Liability Corporation reported 550,000 shares or 0.26% of all its holdings. Burnham Asset Mgmt Ny accumulated 9,974 shares or 0.22% of the stock.
Insider Transactions: Since April 27, 2016, the stock had 1 insider purchase, and 14 selling transactions for $149.60 million net activity. LILLY ENDOWMENT INC sold $16.70 million worth of Eli Lilly and Co (NYSE:LLY) on Tuesday, July 12. Barnes Melissa S sold 992 shares worth $73,180. On Tuesday, October 4 the insider Crowe Maria A sold $182,927. 1,600 shares were sold by Zakrowski Donald A, worth $121,368. TAI JACKSON P bought $205,875 worth of stock. 12,000 shares were sold by Zulueta Alfonso G, worth $915,240 on Wednesday, April 27.
More recent Eli Lilly and Co (NYSE:LLY) news were published by: Prnewswire.com which released: “New Data on the Combination of Lilly’s ALIMTA® (pemetrexed) and Merck’s …” on October 09, 2016. Also Wsj.com published the news titled: “Eli Lilly To Buy Boehringer Ingelheim Pet Vaccines Portolio for $885 Million” on October 05, 2016. Streetinsider.com‘s news article titled: “Eli Lilly & Co. (LLY) to Present Data for Taltz in Psoriasis at EADV” with publication date: September 27, 2016 was also an interesting one.
LLY Company Profile
Eli Lilly and Company, incorporated on January 17, 1901, is engaged in drug manufacturing business. The Firm discovers, develops, makes and markets products in two divisions: human pharmaceutical products and animal health products. The Company’s products are sold in over 120 countries. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. The Company’s animal health business segment operates through the Company’s Elanco division, which develops, makes and markets products for both food animals and companion animals. The Firm makes and distributes its products through facilities in the United States, Puerto Rico and over 10 other countries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.